表紙
市場調查報告書

呼吸道感染診斷市場:按技術,分類,位置,Covid-19地區影響和預測/分析,執行指南和顧問指南(2021-2025)

Respiratory Infection Diagnostic Markets by Technology, Plex, Place and by Region with Covid-19 Impact & Forecasting/Analysis, and Executive and Consultant Guides 2021-2025

出版商 Howe Sound Research 商品編碼 969253
出版日期 內容資訊 英文 347 Pages
商品交期: 最快1-2個工作天內
價格
呼吸道感染診斷市場:按技術,分類,位置,Covid-19地區影響和預測/分析,執行指南和顧問指南(2021-2025) Respiratory Infection Diagnostic Markets by Technology, Plex, Place and by Region with Covid-19 Impact & Forecasting/Analysis, and Executive and Consultant Guides 2021-2025
出版日期: 2020年11月05日內容資訊: 英文 347 Pages
簡介

本報告調查了全球呼吸道感染診斷市場,COVID-19的影響,市場增長和製約因素,發展趨勢,按技術/領域/位置/地區,競爭進行的市場分析。它提供了諸如主要公司的狀況和概況之類的信息。

目錄

I.呼吸道感染診斷市場:策略狀況分析和COVID-19的影響

II.高管,營銷,銷售和業務開發人員指南

III.管理顧問和投資顧問指南

第1章市場介紹和定義

  • 什麼是呼吸道感染?
  • 診斷和治療的作用
  • 市場定義
    • 利潤市場規模
  • 調查方法
  • 臨床測試展望

第2章市場概述

  • 市場進入公司
    • 學術研究室
    • 診斷測試開發人員
    • 儀器供應商
    • 分銷商和試劑供應商
    • 獨立檢查實驗室
    • 國家/地區公共研究所
    • 醫院實驗室
    • 醫生辦公室實驗室
    • 審計機構
    • 認證機構
  • 呼吸道感染
    • 對營銷的影響
    • 肺炎的作用
    • 細菌感染
    • 結核:特殊情況
    • 病毒感染
    • 真菌和其他病原體
  • 診斷:角色變化
    • 歷史實踐
    • 當前診斷
    • 多重向量
    • 未來診斷-何時何地出現問題
    • 呼吸道感染的診斷-目的地
    • 診斷為防禦武器
  • COVID-19
    • 體徵和症狀
    • 感染;感染
    • 診斷
    • 預防
    • 管理
    • 預後
  • 大流行診斷
    • 風險管理:火花和擴散
    • Dx技術:基於核酸
    • Dx技術:免疫測定和血清學
    • 上市時間和準備工作問題
    • 多重傳播在大流行管理中的作用未被認識

第3章市場趨勢

  • 市場增長因素
  • 市場約束因素
  • 儀表和自動化
  • 診斷技術的發展

第4章呼吸道感染診斷的最新進展

  • 最新動態-本節的重要性和用法
    • 這些發展的重要性
    • 如何使用本節
      • GenMark響應對SARS-CoV-2和呼吸板的不斷增長的需求
      • Tempus宣佈大規模COVID-19測試,數據計劃
      • 算盤診斷準備就緒的多重呼吸檢查
      • Qiagen收購NeuMoDx Molecular
      • Dx公司SARS-CoV-2,注意流感的多重檢測
      • Novacyt在日冕病毒,流感,RSV組合面板上獲得CE標誌
      • Mammoth Biosciences宣佈基於CRISPR的COVID-19快速診斷
      • 開髮用於結核病檢測的AI等

第5章主要公司簡介

  • Abacus Diagnostica
  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akkoni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Atlas Genetics
  • Aus Diagnostics
  • BD Diagnostics
  • Biocartis
  • BioFire Diagnostics
  • bioMérieux
  • Bio-Rad Laboratories
  • Bosch Healthcare Solutions GmbH
  • Cepheid
  • Co-Diagnostics
  • Cue Health
  • Curetis
  • Diagenode Diagnostics
  • Diascopic
  • Diasorin
  • Expedeon
  • Fusion Genomics
  • GenePOC Diagnostics
  • Genetic Signatures
  • GenMark Dx
  • Hologic
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Lexigene
  • Luminex
  • Lumos Diagnostics
  • Mammoth Biosciences
  • Mbio Diagnostics
  • Meridian Bioscience
  • Mesa Biotech
  • Mobidiag
  • Nanomix
  • Oxford Nanopore
  • Panagene
  • Primerdesign
  • Prominex
  • Qiagen (Statdx)
  • Quantumdx
  • Quidel
  • Roche Molecular Diagnostics
  • Saw Diagnostics
  • Seegene
  • Sensovation
  • Siemens Healthineers (Fast Track Diagnostics)
  • SkylineDx
  • Sona Nanotech
  • T2 Biosystems
  • Thermo Fisher
  • Veradus Labs
  • Veramarx

第6章全球呼吸道感染診斷市場

  • 按國家:全球市場概述
  • 按技術分類:全球市場概述
  • 通過Plex:全球市場概述
  • 按位置:全球市場概述

第7章世界市場:按技術

  • 微生物學
  • PCR
  • NGS
  • 免疫測定/其他
  • C19單重

第8章世界市場:Plex

  • C19單重
  • 單重
  • 雙面/三層
  • 多重技術

第9章世界市場:按地理位置

  • 醫院實驗室
  • 門診實驗室
  • POC
  • 其他

附錄

  • 美國醫療保險制度:2020年1月臨床檢查費用表
目錄

OVERVIEW:

COVID-19 has broken open the market for point of care testing of respiratory infections. Now the competition for market share begins in earnest. Large new markets are opening up. In health facilities, clinics, physicians' offices and elsewhere. And lets not forget the screening market, not just for COVID, but for the rest of the 20 something respiratory pathogens as well. Multiplex vs single plex? Explore the rapidly changing market as competitors jockey for position in new markets that are not yet well understood.

New technology is forever changing the diagnosis of respiratory infections. Shrinking time to result is opening up markets multiple times the size of current microbiology based practice. Diagnosis has already moved into the Emergency Room. It is now moving to the Physician's Office Lab. Could the Home be next?

The Multiplex factor is creating market confusion while lowering costs and improving care but important factors are holding back progress. The widespread nature of respiratory infections, (young people can get 8 colds a year) means that potential market sizes are enormous. Respiratory, already the largest infectious disease category could multiply in size. This is a growth opportunity for all diagnostic companies. Understand the opportunity and the risk with this in depth report.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Respiratory Infections Diagnostic Market - Strategic Situation Analysis and Impact of COVID-19

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 What are Respiratory Infections?
  • 1.2 The Role of Diagnosis & Treatment
  • 1.3 Market Definition
    • 1.3.1 Revenue Market Size
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 A Spending Perspective on Clinical Laboratory Testing
    • 1.5.1 An Historical Look at Clinical Testing

2. Market Overview

  • 2.1 Players in a Dynamic Market
    • 2.1.1 Academic Research Lab
    • 2.1.2 Diagnostic Test Developer
    • 2.1.3 Instrumentation Supplier
    • 2.1.4 Distributor and Reagent Supplier
    • 2.1.5 Independent Testing Lab
    • 2.1.6 Public National/regional lab
    • 2.1.7 Hospital lab
    • 2.1.8 Physician Office Labs
    • 2.1.9 Audit Body
    • 2.1.10 Certification Body
  • 2.2 Respiratory Infections
    • 2.2.1 Upper vs. Lower - Marketing Implications
    • 2.2.2 Understanding the Role of Pneumonia
    • 2.2.3 Bacterial Infections
      • 2.2.3.1 Streptococcal Infections
      • 2.2.3.2 Acute Otitis Media
      • 2.2.3.3 Bacterial Rhinosinusitis
      • 2.2.3.4 Diphtheria
      • 2.2.3.5 Pneumococcal Pneumonia
      • 2.2.3.6 Haemophilus Pneumonia
      • 2.2.3.7 Mycoplasma Pneumonia (Walking Pneumonia)
      • 2.2.3.8 Chlamydial Pneumonias and Psittacosis
      • 2.2.3.9 Health Care-Associated Pneumonia
      • 2.2.3.10 Pseudomonas Pneumonia
      • 2.2.3.11 Pertussis (Whooping Cough)
      • 2.2.3.12 Legionnaires Disease
    • 2.2.4 Tuberculosis - A Special Case
    • 2.2.5 Viral Infections
      • 2.2.5.1 The Common Cold
      • 2.2.5.2 Influenza
      • 2.2.5.3 Viral Pneumonia
      • 2.2.5.4 SARS and MERS
      • 2.2.5.5 Measles (Rubeola)
      • 2.2.5.6 Rubella (German Measles)
      • 2.2.5.7 Chickenpox and Shingles
    • 2.2.6 Fungal and Other Pathogens
      • 2.2.6.1 Histoplasmosis
      • 2.2.6.2 Coccidioidomycosis
      • 2.2.6.3 Blastomycosis
      • 2.2.6.4 Mucormycosis
      • 2.2.6.5 Aspergillosis
      • 2.2.6.6 Pneumocystis Pneumonia
      • 2.2.6.7 Cryptococcosis
  • 2.3 Diagnostics - A Changing Role
    • 2.3.1 Historical Practice
    • 2.3.2 Current Diagnostics
    • 2.3.3 The Multiplex Vector
    • 2.3.4 Future Diagnostics - The Question of When and Where
    • 2.3.5 Respiratory Infection Diagnostics - The Destination
    • 2.3.6 Diagnostics as Defensive Weapons
  • 2.4 COVID-19
    • 2.4.1 Signs and symptoms
    • 2.4.2 Transmission
    • 2.4.3 Diagnosis
    • 2.4.4 Prevention
    • 2.4.5 Management
    • 2.4.6 Prognosis
  • 2.5 Pandemic Diagnostics
    • 2.5.1 Risk Management - Spark and Spread
    • 2.5.2 Dx Technology - Nucleic Acid Based
    • 2.5.3 Dx Technology - Immunoassay & Serology
    • 2.5.4 Time to Market and Preparedness Issues
    • 2.5.5 Unrecognized Role of Multiplex in Pandemic Mangement

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 Syndromic Multiplexing
    • 3.1.2 T.A.T
    • 3.1.3 Antimicrobial Resistance Movement
    • 3.1.4 Pandemic Mitigation
    • 3.1.5 An Aging at Risk Population
  • 3.2 Factors Limiting Growth
    • 3.2.1 The Cost Curve
    • 3.2.2 Regulation and coverage
    • 3.2.3 Laissez Faire
  • 3.3 Instrumentation and Automation
    • 3.3.1 The Shrinking Multiplexing Machine
    • 3.3.2 Bioinformatics Networking and Anonymous Reporting
  • 3.4 Diagnostic Technology Development
    • 3.4.1 The Key Role of Time to Result
    • 3.4.2 Single Cell Genomics Changes the Picture
    • 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.4 Pathogen Identification - A Projected Timetable of the Future

4. Respiratory Infection Diagnostics Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
      • GenMark to Meet Pent Up Demand for SARS-CoV-2, Respiratory Panel
      • Tempus Announces Large-Scale COVID-19 Testing, Data Initiative
      • Abacus Diagnostica Readying Multiplex Respiratory Test
      • Qiagen Acquires NeuMoDx Molecular
      • Dx Companies Shift Attention to Multiplex Tests for SARS-CoV-2, Influenza
      • Novacyt Gets CE Mark for Coronavirus, Flu, RSV Combo Panel
      • Cepheid Debuts 10-Color Technology With New Tuberculosis Test
      • BioMérieux's Pneumonia Panel Could Improve Care
      • Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
      • Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
      • Qiagen Respiratory Panel with Coronavirus Receives CE Mark
      • Lumos Diagnostics Closes $15M Series A Funding
      • Fusion Genomics Wins $1M to Assess NGS-Based Respiratory Tract Infection Assay
      • Coronavirus Detection Test Development by Co-Diagnostics
      • Rapid Diagnostics Completes Asset Purchase of Enigma Diagnostics
      • Flu-Like Epidemic Could Kill 80 Mn Globally
      • Startup developing AI for TB detection
      • Nipah Virus a Global Threat
      • Novacyt S.A.: New Molecular Respiratory Panel Ready for US Market
      • New DRC Ebola cases confirmed as FDA OKs rapid test
      • CE Mark for Smartphone-based Diagnostic Test for Adult Respiratory Disease
      • Curetis Submits Lower Respiratory Tract Infection Test for FDA Clearance
      • New rapid test diagnoses pneumonia and other lower respiratory infections
      • Ontera Awarded Contract for Zika Genotyping Test
      • Two New Members Join Global Diagnostics Network
      • BARDA Funding Health Security Solutions

5. Profiles of Key Players

  • Abacus Diagnostica
  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akkoni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Atlas Genetics
  • Aus Diagnostics
  • BD Diagnostics
  • Biocartis
  • BioFire Diagnostics
  • bioMérieux
  • Bio-Rad Laboratories
  • Bosch Healthcare Solutions GmbH
  • Cepheid
  • Co-Diagnostics
  • Cue Health
  • Curetis
  • Diagenode Diagnostics
  • Diascopic
  • Diasorin
  • Expedeon
  • Fusion Genomics
  • GenePOC Diagnostics
  • Genetic Signatures
  • GenMark Dx
  • Hologic
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Lexigene
  • Luminex
  • Lumos Diagnostics
  • Mammoth Biosciences
  • Mbio Diagnostics
  • Meridian Bioscience
  • Mesa Biotech
  • Mobidiag
  • Nanomix
  • Oxford Nanopore
  • Panagene
  • Primerdesign
  • Prominex
  • Qiagen (Statdx)
  • Quantumdx
  • Quidel
  • Roche Molecular Diagnostics
  • Saw Diagnostics
  • Seegene
  • Sensovation
  • Siemens Healthineers (Fast Track Diagnostics)
  • SkylineDx
  • Sona Nanotech
  • T2 Biosystems
  • Thermo Fisher
  • Veradus Labs
  • Veramarx

6. The Global Market for Respiratory Infection Diagnostics

  • 6.1 Global Market Overview by Country
    • 6.1.1 Table - Global Market by Country
    • 6.1.2 Chart - Global Market by Country
  • 6.2 Global Market by Technology - Overview
    • 6.2.1 Table - Global Market by Technology
    • 6.2.2 Chart - Global Market by Technology - Base/End Year Comparison
    • 6.2.3 Chart - Global Market by Technology - Base Year
    • 6.2.4 Chart - Global Market by Technology - End Year
    • 6.2.5 Chart - Global Market by Technology - Share by Year
  • 6.3 Global Market by Plex - Overview
    • 6.3.1 Table - Global Market by Plex
    • 6.3.2 Chart - Global Market by Plex - Base/End Year Comparison
    • 6.3.3 Chart - Global Market by Plex - Base Year
    • 6.3.4 Chart - Global Market by Plex - End Year
    • 6.3.5 Chart - Global Market by Plex - Share by Year
  • 6.4 Global Market by Place - Overview
    • 6.4.1 Table - Global Market by Place
    • 6.4.2 Chart - Global Market by Place - Base/End Year Comparison
    • 6.4.3 Chart - Global Market by Place - Base Year
    • 6.4.4 Chart - Global Market by Place - End Year
    • 6.4.5 Chart - Global Market by Place - Share by Year

7. Global Respiratory Infection Diagnostic Markets - By Technology

  • 7.1 Microbiology
    • 7.1.1 Table Microbiology - by Country
    • 7.1.2 Chart - Microbiology Growth
  • 7.2 PCR
    • 7.2.1 Table PCR - by Country
    • 7.2.2 Chart - PCR Growth
  • 7.3 NGS
    • 7.3.1 Table NGS - by Country
    • 7.3.2 Chart - NGS Growth
  • 7.4 Immunoassay/Other
    • 7.4.1 Table Immunoassay - by Country
    • 7.4.2 Chart - Immunoassay/Other Growth
  • 7.5 C19 Singleplex
    • 7.5.1 Table C19splex - by Country
    • 7.5.2 Chart - C19splex Growth

8. Global Respiratory Infection Diagnostic Markets - by Plex

  • 8.1 C19 Single Plex
    • 8.1.1 Table C19 Single Plex - by Country
    • 8.1.2 Chart - C19 Single Plex Growth
  • 8.2 Singleplex
    • 8.2.1 Table Singleplex - by Country
    • 8.2.2 Chart - Singleplex Growth
  • 8.3 Duplex/Triplex
    • 8.3.1 Table Duplex/Triplex - by Country
    • 8.3.2 Chart - Duplex/Triplex Growth
  • 8.4 Multiplex Technology
    • 8.4.1 Table Multiplex - by Country
    • 8.4.2 Chart - Multiplex Growth

9. Global Respiratory Infection Diagnostic Markets - by Place

  • 9.1 Hospital Lab
    • 9.1.1 Table Hospital Lab - by Country
    • 9.1.2 Chart - Hospital Lab Growth
  • 9.2 Outpatient Lab
    • 9.2.1 Table Outpatient Lab - by Country
    • 9.2.2 Chart - Outpatient Lab Growth
  • 9.3 POC
    • 9.3.1 Table POC - by Country
    • 9.3.2 Chart - POC Growth
  • 9.4 Other Technology
    • 9.4.1 Table Other - by Country
    • 9.4.2 Chart - Other Growth

Appendices

  • I. United States Medicare System: January 2020 Clinical Laboratory Fees Schedule

Table of Tables

  • Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2020 ($million)
  • Table 2 Market Players by Type
  • Table 3 Bacterial Causes of Pneumonia
  • Table 4 List of Influenza Pandemics
  • Table 5 Viral Infections of the Respiratory Tract
  • Table 6 Fungal Infections of the Respiratory Tract
  • TABLE 7 CHARACTERISTICS OF CORONAVIRUS PANDEMIC INFECTIONS
  • TABLE 8 COVID-19 SYMPTOMS
  • Table 9 Five Factors Driving Growth
  • Table 10 Three Factors Limiting Growth
  • Table 11 Key Diagnostic Laboratory Technology Trends
  • Table 12 Long Term Pathoghen Identification Timetable
  • Table 13 - Global Market by Region
  • Table 14 Global Market by Technology
  • Table 15 Global Market by Plex
  • Table 16 Global Market by Place
  • Table 17 Microbiology by Country
  • Table 18 PCR by Country
  • Table 19 NGS by Country
  • Table 20 Immunoassay/Other by Country
  • Table 21 C19splex by Country
  • Table 22 C19 Single Plex by Country
  • Table 23 Singleplex by Country
  • Table 24 Duplex/Triplex by Country
  • Table 25 Multiplex by Country
  • Table 26 Hospital Lab by Country
  • Table 27 Outpatient Lab by Country
  • Table 28 POC by Country
  • Table 29 Other by Country
  • Table 30 2020 Laboratory Fee Schedule

Table of Figures

  • Figure 1 Upper vs. Lower Respiratory Tract
  • Figure 2 The LRI Mortality Rate Globally
  • Figure 3 Global Pandemic Pathogen Status
  • Figure 4 Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
  • Figure 5 The BioFire Respiratory Panel
  • Figure 6 Pneumonia
  • Figure 7 Bacterial Infections of the Respiratory Tract
  • Figure 8 The Development Cycle of Tuberculosis
  • Figure 9 A Flu Epidemic in Europe - Historical Pattern
  • Figure 10 The Multiplex Paradigm Shift
  • Figure 11 Percentage of World Population Over 65
  • Figure 12 Global Market Share Chart
  • Figure 13 Global Market by Technology - Base vs. End Year
  • Figure 14 Global Market by Technology Base Year
  • Figure 15 Global Market by Technology End Year
  • Figure 16 Technology Share by Year
  • Figure 17 Plex - Base vs. End Year Segment Shift
  • Figure 18 Plex Market Base Year
  • Figure 19 Plex Market End Year
  • Figure 20 Plex Share by Year
  • Figure 21 Place - Base vs. End Year
  • Figure 22 Place Market Base Year
  • Figure 23 Place Market End Year
  • Figure 24 Place Share by Year
  • Figure 25 Microbiology Growth
  • Figure 26 PCR Diagnostics Growth
  • Figure 27 NGS Growth
  • Figure 28 Immunoassay/Other Growth
  • Figure 29 C19splex Growth
  • Figure 30 C19 Single Plex Growth
  • Figure 31 Singleplex Growth
  • Figure 32 Duplex/Triplex Growth
  • Figure 33 Multiplex Growth
  • Figure 34 Hospital Lab Growth
  • Figure 35 Outpatient Lab Growth
  • Figure 36 POC Growth
  • Figure 37 Other Growth